Related Experiment Videos
Cytokine fusion protein treatment
David Schrama1, Per thor Straten, Eva-Bettina Bröcker
1Department of Dermatology, Julius Maximilians University, Würzburg, Germany.
Abstract:
Mice suffering from melanoma can be cured by treatment with a recombinant antibody-lymphotoxin-alpha fusion protein. In order to characterize the involvement of T cells in this syngeneic tumor model, the T cell receptor repertoire was analyzed both quantitatively and qualitatively. In this connection, quantitative analysis of the T cell receptors displayed only a modest overexpression in some of the variable beta chain families over the course of therapy. Clonotypic mapping, however, revealed a marked increase in the number of clonally expanded T cells among the tumor-infiltrating T cells, suggesting a specific activation.
Insights
Recombinant antibody-lymphotoxin-alpha fusion protein therapy cures melanoma in mice. T cell analysis revealed significant clonal expansion in tumor-infiltrating T cells, indicating specific immune activation during treatment.
Area of Science:
- Immunology
- Oncology
- Biotechnology
Background:
- Melanoma is a significant health concern.
- Novel therapeutic strategies are needed for melanoma treatment.
- Understanding the immune response to cancer therapy is crucial.
Purpose of the Study:
- To investigate the role of T cells in a murine melanoma model treated with a novel fusion protein.
- To characterize the T cell receptor repertoire during anti-melanoma therapy.
Main Methods:
- Treatment of melanoma-bearing mice with a recombinant antibody-lymphotoxin-alpha fusion protein.
- Quantitative and qualitative analysis of the T cell receptor repertoire.
- Clonotypic mapping of tumor-infiltrating T cells.
Main Results:
- Quantitative T cell receptor analysis showed modest overexpression in some variable beta chain families.
- Clonotypic mapping revealed a significant increase in clonally expanded T cells within tumors.
- These findings suggest a specific T cell activation in response to therapy.
Conclusions:
- The recombinant antibody-lymphotoxin-alpha fusion protein effectively treats melanoma in mice.
- Therapy induces a specific and clonal T cell response within the tumor microenvironment.
- This highlights the importance of T cell-mediated immunity in the efficacy of this novel therapeutic approach.